Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ESR1 | P03372 | 12/20 | 0.43 |
| ▸ | ESR2 | Q92731 | 9/20 | 0.43 |
| ▸ | MLNR | O43193 | 1/20 | 0.38 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.38 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.38 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.38 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.38 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.38 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.38 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.38 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.38 |
| ▸ | NPY1R | P25929 | 1/20 | 0.38 |
| ▸ | HTR2A | P28223 | 1/20 | 0.38 |
| ▸ | HTR2C | P28335 | 1/20 | 0.38 |
| ▸ | AVPR2 | P30518 | 1/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Trifluoroacetic Acid SCHEMBL5108860 | 0.99 | ESR1 (0.42) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Trifluoroacetic Acid SCHEMBL5114107 | 0.95 | ESR1 (0.40) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL5114928 | 0.93 | ESR1 (0.40) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL5109392 | 0.92 | ESR1 (0.40) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Trifluoroacetic Acid SCHEMBL5101624 | 0.90 | ESR1 (0.45) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL5113793 | 0.90 | ESR1 (0.37) | ESR1ESR2SLC6A2ADRA1AOPRK1 | |
| SCHEMBL5108854 | 0.89 | ESR1 (0.36) | ESR1ESR2SLC6A2ADRA1AOPRK1 | |
| Trifluoroacetic Acid SCHEMBL5104783 | 0.88 | ESR1 (0.42) | ESR1ESR2MLNRNR1I2NR3C1 | |
| SCHEMBL5116826 | 0.88 | ESR1 (0.38) | ESR1ESR2MLNRNR1I2NR3C1 | |
| Trifluoroacetic Acid SCHEMBL5106301 | 0.87 | ESR1 (0.49) | ESR1ESR2MLNRNR1I2NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7435729-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2008-10-14 | — | — | US | disclosed |
| US-7279489-B2 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, LLC (US) | 2007-10-09 | — | — | US | disclosed |
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2005-01-06 | — | — | US | disclosed |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2004-04-29 | — | — | US | disclosed |
| US-6686351-B2 | PARTIALLY HYDROGENATED FUSED INDENE, NAPHTHALENE, ISOINDOLE, ISOQUINOLINE, BENZOAZEPINE AND BENZOCYCLOHEPTENE DERIVATIVES SUBSTITUTED BY A HYDROXY GROUP OR DERIVATIVE AND AN ARYL OR N-HETEROARYL GROUP | SIGNAL PHARMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6593322-B1 | Methods are disclosed for modulating ER- beta in cell and/or tissues expressing the same, including cells and/ or tissue that preferentially ER- beta . Methods for treating estrogen-related conditions are also disclosed, including | SIGNAL PHARMACEUTICALS, INC. | 2003-07-15 | — | — | US | disclosed |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | SIGNAL PHARMACEUTICALS, INC. | 2003-05-08 | — | — | US | disclosed |
| US-6436923-B1 | ESTROGEN ANTAGONISTS AND/OR AGONISTS FOR TREATING ESTROGEN-RELATED CONDITIONS | SIGNAL PHARMACEUTICALS, INC. | 2002-08-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050004360-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESR2, ESRRA | ESR1 5/4885ESR2 2/4885MLNR 1967/4885 |
| US-20030087901-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | ESR1 5/4885ESR2 3/4885MLNR 1411/4885 |
| US-20040082575-A1 | Compounds and methods for modulation of estrogen receptors | ESRRB, ESRRA, ESR2 | ESR1 6/4885ESR2 3/4885MLNR 1531/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.